- Home
- INVA vs ADPT Comparison
INVA vs ADPT Comparison
Compare INVA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- ADPT
- Stock Information
- Founded
- INVA 1996
- ADPT 2009
- Country
- INVA United States
- ADPT United States
- Employees
- INVA N/A
- ADPT N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INVA Health Care
- ADPT Health Care
- Exchange
- INVA Nasdaq
- ADPT Nasdaq
- Market Cap
- INVA 1.4B
- ADPT 1.4B
- IPO Year
- INVA 2004
- ADPT 2019
- Fundamental
- Price
- INVA $19.21
- ADPT $11.80
- Analyst Decision
- INVA Buy
- ADPT Strong Buy
- Analyst Count
- INVA 1
- ADPT 7
- Target Price
- INVA $55.00
- ADPT $10.57
- AVG Volume (30 Days)
- INVA 1.1M
- ADPT 2.2M
- Earning Date
- INVA 07-30-2025
- ADPT 07-31-2025
- Dividend Yield
- INVA N/A
- ADPT N/A
- EPS Growth
- INVA N/A
- ADPT N/A
- EPS
- INVA N/A
- ADPT N/A
- Revenue
- INVA $369,844,000.00
- ADPT $189,527,000.00
- Revenue This Year
- INVA $3.75
- ADPT $24.46
- Revenue Next Year
- INVA $12.62
- ADPT $20.25
- P/E Ratio
- INVA N/A
- ADPT N/A
- Revenue Growth
- INVA 18.70
- ADPT 8.61
- 52 Week Low
- INVA $16.19
- ADPT $3.30
- 52 Week High
- INVA $22.00
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- INVA 32.74
- ADPT 66.39
- Support Level
- INVA $19.68
- ADPT $11.17
- Resistance Level
- INVA $21.97
- ADPT $12.43
- Average True Range (ATR)
- INVA 0.60
- ADPT 0.60
- MACD
- INVA -0.31
- ADPT 0.03
- Stochastic Oscillator
- INVA 5.74
- ADPT 75.10
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).